Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Amino acids; Fludeoxyglucose F-18; Gallium 68-DOTATATE
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- Acronyms 177Lu-DOTATATE trial
- 30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.
- 30 Jun 2022 According to a Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified. Company restarted screening and enrollment for clinical trials with Lutathera in the US and Canada.
- 05 May 2022 According to Novartis media release, status changed from recruiting to suspended as Novartis is putting a temporary hold on screening and enrollment for Lutathera clinical trials in the US and Canada.